BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mueller JL, Feeney ER, Zheng H, Misdraji J, Kruger AJ, Alatrakchi N, King LY, Gelrud L, Corey KE, Chung RT. Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2015;6:e114. [PMID: 26448455 DOI: 10.1038/ctg.2015.36] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 44.3] [Reference Citation Analysis]
2 Price JC, Wang R, Seaberg EC, Budoff MJ, Kingsley LA, Palella FJ, Witt MD, Post WS, Thio CL. The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus. Open Forum Infect Dis 2017;4:ofx153. [PMID: 28929125 DOI: 10.1093/ofid/ofx153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rødgaard-hansen S, St. George A, Kazankov K, Bauman A, George J, Grønbæk H, Jon Møller H. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation 2017;77:498-504. [DOI: 10.1080/00365513.2017.1346823] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
4 Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 2018;218:1394-403. [PMID: 29868909 DOI: 10.1093/infdis/jiy331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
5 Lemoine M, Lacombe K, Bastard JP, Sébire M, Fonquernie L, Valin N, Fellahi S, Capeau J, Girard PM, Meynard JL. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients. AIDS 2017;31:1955-64. [PMID: 28692538 DOI: 10.1097/QAD.0000000000001587] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 6.8] [Reference Citation Analysis]
6 Kazankov K, Alisi A, Møller HJ, De Vito R, Rittig S, Mahler B, Nobili V, Grønbæk H. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2018;67:635-42. [PMID: 30074574 DOI: 10.1097/MPG.0000000000002111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
7 Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Younes R, Esmaili S, Eslam M, McLeod D, Bibby BM, Vilstrup H, George J, Grønbaek H. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int 2016;36:1549-57. [PMID: 27102725 DOI: 10.1111/liv.13150] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 10.2] [Reference Citation Analysis]
8 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Reference Citation Analysis]
9 Corey KE, Wilson LA, Altinbas A, Yates KP, Kleiner DE, Chung RT, Krauss RM, Chalasani N; NASH Clinical Research Network. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. Aliment Pharmacol Ther 2019;49:1205-13. [PMID: 30854694 DOI: 10.1111/apt.15216] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
10 Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, Young BJ, Sung JC, Miller KK. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2017;8:e217. [PMID: 28125073 DOI: 10.1038/ctg.2016.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
11 Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, Long MT. Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clin Gastroenterol Hepatol 2019; 17: 1157-1164. e4. [PMID: 30476583 DOI: 10.1016/j.cgh.2018.11.037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
12 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Thomsen KL, Robertson FP, Holland-Fischer P, Davidson BR, Mookerjee RP, Møller HJ, Jalan R, Grønbæk H. The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation. J Clin Exp Hepatol 2019;9:302-11. [PMID: 31360022 DOI: 10.1016/j.jceh.2018.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. Front Med (Lausanne) 2020;7:616212. [PMID: 33392234 DOI: 10.3389/fmed.2020.616212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Welsh JA, Scorletti E, Clough GF, Englyst NA, Byrne CD. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. J Leukoc Biol 2018;104:631-9. [DOI: 10.1002/jlb.5a1217-501r] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Tseng SH, Chang TY, Shih CK, Hsieh RH, Chen CW, Chen YC, Lin MH, Chang JS. Effect of Endoplasmic Reticular Stress on Free Hemoglobin Metabolism and Liver Injury. Int J Mol Sci 2018;19:E1977. [PMID: 29986432 DOI: 10.3390/ijms19071977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Fourman LT, Czerwonka N, Shaikh SD, Stanley TL, Burdo TH, Williams KC, Fitch KV, Lo J, Grinspoon SK. Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS 2018;32:927-32. [PMID: 29424780 DOI: 10.1097/QAD.0000000000001775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, Guigues A, Merle C, Atoui N, Fernandez C, Le Moing V, Barbuat C, Marin G, Nagot N, Sotto A, Eliaou JF, Sabatier R, Reynes J, Corbeau P. One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study. EBioMedicine 2016;8:265-76. [PMID: 27428436 DOI: 10.1016/j.ebiom.2016.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
19 Kirkegaard-Klitbo DM, Mejer N, Knudsen TB, Møller HJ, Moestrup SK, Poulsen SD, Kronborg G, Benfield T. Soluble CD163 predicts incident chronic lung, kidney and liver disease in HIV infection. AIDS 2017;31:981-8. [PMID: 28252527 DOI: 10.1097/QAD.0000000000001432] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
20 Nielsen MC, Hvidbjerg Gantzel R, Clària J, Trebicka J, Møller HJ, Grønbæk H. Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. Cells 2020;9:E1175. [PMID: 32397365 DOI: 10.3390/cells9051175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
21 Ragab HM, El Maksoud NA, Amin MA, Elaziz WA. Performance of serum CD163 as a marker of fibrosis in patients with NAFLD. Diabetes Metab Syndr 2021;15:87-92. [PMID: 33310266 DOI: 10.1016/j.dsx.2020.11.023] [Reference Citation Analysis]
22 Ma Y, Yang M, He Z, Wei Q, Li J. The Biological Function of Kupffer Cells in Liver Disease. In: Ghosh A, editor. Biology of Myelomonocytic Cells. InTech; 2017. [DOI: 10.5772/67673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Aboushousha T, Emad M, Rizk G, Ragab K, Hammam O, Fouad R, Helal NS. IL-4, IL-17 and CD163 Immunoexpression and IL-6 Gene Polymorphism in Chronic Hepatitis C Patients and Associated Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1105-13. [PMID: 33906302 DOI: 10.31557/APJCP.2021.22.4.1105] [Reference Citation Analysis]
24 Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases. Int J Mol Sci 2020;21:E5497. [PMID: 32752088 DOI: 10.3390/ijms21155497] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
25 Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM. Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH. Diabetes Metab Syndr Obes 2020;13:3861-72. [PMID: 33116732 DOI: 10.2147/DMSO.S249949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]